Press Releases

Endonovo Therapeutics Announces Corporate Patent Licensing Program

Download PDF

LOS ANGELES, CA -- (Marketwired) -- 09/16/15 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a biotechnology company developing non-invasive, bioelectronic products with anti-inflammatory properties designed to promote regeneration in damaged tissue and organs, announced today the commencement of the Company's patent licensing program. The first of several patent applications filed with the United States Patent and Trademark Office is currently available for licensing to potential corporate partners.

Initially, the technology being offered by the Company for licensing opportunities is a composition and process patent. The patent covers a composition and process for creating a cell mixture derived from a portion of the umbilical cord co-cultured with adipose-derived stem cells. The resulting mixture provides a rich source of highly proliferative, biologically potent, immunosuppressive and non-alloreactive cells that display neither of the major histocompatibility markers (HLA double negative). Therefore, the cell mixture can be used as either an autologous or an allogeneic off-the-shelf source for cell-based therapeutics.

The patent covers a broad range of applications from skeletal tissue regeneration to the treatment of a wide array of non-genetic diseases and conditions.

Adult stem cells present a promising model for regenerative medicine and tissue engineering as cells obtained from the bone marrow have traditionally been the most common source for cell-based therapies. However, bone marrow-derived and other adult stem cells require invasive procurement procedures, provide a relatively low frequency of progenitors, and have a relatively low capacity for self-renewal.

According to Transparency Market Research, the global stem cell market could reach US$119.52 billion by 2019; increasing from US$26.23 billion in 2013, a 24.2% CAGR between 2012 and 2018. This trend will most likely be driven by a substantial consumer demand for stem cell banking and the R&D undertakings worldwide from both public and private healthcare agencies. Due to their relative ease of harvesting, the adult stem cell segment is expected to experience faster growth in the coming years. Adult stem cells are divided into cord blood type stem cells, hematopoietic stem cells, mesenchymal stem cells, dental type stem cells, and neuronal stem cells. The market for the storage and cryopreservation of stem cells, particularly cord blood type stem cells, is expected to increase significantly as new therapies are developed.

Alan Collier, CEO of Endonovo Therapeutics, commented, "Endonovo's concentration is on the development of Time-Varying Electromagnetic Field (TVEMF) technology. Beyond TVEMF, we have developed several technologies designed to treat a variety of unmet medical needs. We are protecting our intellectual property, while advancing the development of our non-invasive, electromagnetic products. The current technology we are seeking to license should be extremely beneficial in the international marketplace where non-genetic diseases represent a very large and potentially lucrative opportunity. We look forward to working with the right partners to build out the treatments of the future."

About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a publicly traded biotechnology company developing off the-shelf, cell-free regenerative products and non-invasive, bioelectronic therapies designed to extend and enhance the human life by regenerating tissues and organs that have become injured or damaged due to disease and age. The Company is developing therapies for various inflammatory, autoimmune and degenerative diseases utilizing their bio-electromagnetic platform.

Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108

Media Relations Contact:
PCG Advisory Group
Sean Leous
Chief Communications Officer
(646) 863-8998

Source: Endonovo Therapeutics, Inc.